Business Context and Reporting Period
This Form 8-K Current Report was filed by BioCardia, Inc. (BCDA) on December 4, 2024. The report covers a specific corporate event occurring on the same date regarding the company's lead therapeutic asset, BCDA-01, which is intended for the treatment of ischemic heart failure of reduced ejection fraction.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory milestone and does not contain financial statements or performance data.
Material Changes
The material event reported is the successful completion of a consultation with Japan's Pharmaceutical and Medical Device Agency (PMDA). This consultation addressed the next steps for the registration submission of BCDA-01 in Japan. No financial or operational changes compared to a prior period are detailed in this document.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the successful PMDA consultation. The filing does not provide specific financial guidance, updated outlooks, or a detailed discussion of risks and contingencies beyond the context of the regulatory submission process. The press release attached as Exhibit 99.1 contains further details on the event.
Investor Verification Checklist
- Verify the specific timeline and requirements for the BCDA-01 registration submission in Japan following the PMDA consultation.
- Review the attached press release (Exhibit 99.1) for detailed outcomes of the consultation.
- Confirm the current cash runway and funding status of the company, as this 8-K does not disclose liquidity metrics.
- Monitor future filings for the actual submission date of the registration application to the PMDA.